Polineuropatia desmielinizante inflamatória crônica – uma revisão narrativa by Meireles, André Luís Ferreira




Chronic inflammatory demyelinating polyradiculoneuropathy – a narrative review
Polineuropatia desmielinizante inflamatória crônica – uma revisão narrativa 
André Luís Ferreira Meireles
Meireles ALF. Chronic inflammatory demyelinating polyradiculoneuropathy – a narrative review / Polineuropatia desmielinizante 
inflamatória crônica – uma revisão narrativa. Rev Med (São Paulo). 2021 Jan-Feb;100(1):57-61.
Neurologic Physical Therapist, Ph.D. in Neuroscience, Physical Therapy Department of Centro Universitário Unifacvest, Lages, SC. Universidade do 
Estado de Santa Catarina – UDESC, Centro de Ciências da Saúde e do Esporte – CEFID. Florianópolis, SC. https://orcid.org/0000-0002-1751-5022. 
E-mail: meireles.alf@gmail.com.
Correspondence: André Luís Ferreira Meireles. Av. Mal. Floriano, 947 - Centro – Lages, SC. CEP: 88503-190
ABSTRACT: Introduction: Chronic inflammatory demyelinating 
polyradiculoneuropathy (CIDP) is an autoimmune disease 
generated by cellular and humoral immune responses, that act 
in a synergistic way, will act against antigens of the peripheral 
nerves, generating a progressive clinical feature of sensorimotor 
weakness that will change the quality of life of this patient. 
Aim: Summarize the basic and actual concepts of CIDP, such 
as etiology, disease subtypes, clinical features, pathogenesis, 
pharmacological and non-pharmacological treatment. Material 
and Methods: This is a narrative systematic review. Medline 
(Pubmed), Embase and PEDro databases were used to summarize 
the review’ topics. The studies used in this review were selected 
by convenience. Results: CIDP can affect children and adults, and 
male gender is the most affected. The clinical picture of CIDP 
is composed of numbness, paresthesia, sensory changes, muscle 
weakness, hyporeflexia or areflexia, fatigue and balance changes, 
this picture has a progressive or relapsing character, symmetrical 
and with slow evolution. The disease has an autoimmune character 
generated by cellular and humoral immune responses, which will 
act against peripheral nerve antigens, generating demyelination 
and axonal degeneration. The treatment of CIDP aims to reduce or 
attenuate the evolution of symptoms. The main types of treatments 
are the intravenous of immunoglobulins, corticosteroid, and 
plasma transfer administration. Conclusion: Studies exploring 
more deeply the pathophysiological mechanisms of CIDP and 
optimization of diagnosis, are important points that should be 
investigated to improve care and assertiveness in the treatment 
of these patients.
Keywords: Acute inflammatory demyelinating polyneuropathy; 
Physiotherapy; Guillain-Barre syndrome.
RESUMO: Introdução: A Polineuropatia Desmielinizante 
Inflamatória Crônica (PDIC) é uma doença de caráter autoimune 
gerada por respostas imunes celulares e humorais que, atuando de 
forma sinérgica, irão agir contra antígenos dos nervos periféricos, 
gerando um quadro progressivo de debilidade sensório-motora 
que irá alterar a qualidade de vida de seus portadores. Objetivo: 
Sumarizar os conceitos básicos e atuais da PDIC, como etiologia, 
subtipos da doença, quadro clínico, patogênese e o tratamento 
farmacológico e não farmacológico. Material e Métodos: Trata-se 
de uma revisão sistemática narrativa. As bases de dados Medline 
(Pubmed), Embase e PEDro foram utilizadas para sumarizar os 
tópicos dessa revisão. Os estudos que compuseram os tópicos 
dessa revisão foram selecionados por conveniência. Resultados: 
A PDIC pode acometer crianças e adultos, e o sexo masculino é o 
mais afetado. O quadro clínico da PDIC é composto de dormência, 
parestesia, alterações sensoriais, fraqueza muscular, hiporeflexia 
ou arreflexia, fadiga e alterações de equilíbrio, esse quadro tem 
caráter progressivo ou recidivante, simétrico e com evolução 
lenta. A doença tem caráter autoimune gerada por respostas 
imunes celulares e humorais, que irão agir contra antígenos dos 
nervos periféricos, gerando uma desmielinização e degeneração 
axonal. O tratamento da PDIC visa reduzir ou atenuar a evolução 
da sintomatologia. Os principais tipos de tratamentos são a 
administração intravenosa de imunoglobulinas, corticosteroides 
e transferência plasmática. Considerações Finais: Estudos 
explorando mais profundamente os mecanismos fisiopatológicos 
da PDIC e otimização do diagnóstico, são pontos importantes 
que deverão ser investigados para a melhora da assistência e 
assertividade do tratamento desses pacientes.
Palavras-chave: Polineuropatia desmielinizante inflamatória 
aguda, fisioterapia, Síndrome de Guillain-Barré.
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INTRODUCTION
Chronic  in f lammatory  demyel ina t ing polyneuropathy (CIDP) is the most common 
form of chronic autoimmune neuropathy1. CIDP can 
present in its relapsing or progressive form, with proximal 
and distal muscle weakness that develops for at least two 
months2,3.
CIDP is most commonly seen in men and usually 
occurs between the fourth and sixth decade of life; however, 
CIDP can also be seen in children4. The progressive 
evolution of this disease generates symptoms that may 
cause physical and functional limitations and negatively 
impacts the patient’s quality of life5.
In view of the scarcity of national and international 
articles on this pathology, the aim of this article is to briefly 
summarize the basic and current concepts of CIDP, such as 
the subtypes of the disease, epidemiological data, clinical 
presentation, pathogenesis, and pharmacological and non-
pharmacological treatment.
MATERIAL AND METHODS
This is a narrative systematic review. The MEDLINE 
(PubMed), Embase and PEDro (Physiotherapy Evidence 
Database) databases were used, and only English articles 
were selected. The research in these databases included 
clinical trial and systematic review studies, which addressed 
the general aspects of the disease covered in this review 
(definition, epidemiology, etiopathogenesis, clinical 
presentation, pathogenesis, and treatment).
The studies selected to contemplate the definitions 
and topics of this review were chosen from these databases 
for convenience. Thus, the articles included in this narrative 
review were read in an analytical and interpretative way to 
give broader meaning to the findings and definitions found.
RESULTS AND DISCUSSION
Epidemiology
 The prevalence of CIDP has ranged from 1 to 
7.7 per 100,000. Although it is considered a rare disease, 
CIDP is the most common form of chronic autoimmune 
neuropathy. Due to its diversity of clinical presentations 
and the absence of a specific marker for its diagnosis, 
epidemiological studies present values that differ from its 
incidence6,7.
CIDP can also affect children, usually between 5 
and 18 years old. However, peak incidence occurs in adults 
between 40 and 60 years of age. Males are more commonly 
affected by this disease7.
Distinguishing CIDP from Guillain-Barré Syndrome
CIDP and acute inflammatory demyelinating 
polyradiculoneuropathy, also known as Guillain-Barré 
syndrome (GBS), share several clinical features, similarities, 
and electrophysiological and histopathological findings; 
however, the beginning of the diseases’ appearances, 
the peak and course of their symptoms and their clinical 
presentation are distinct1.
GBS is a monophasic disease that is generally 
associated with a previous event, such as a vaccine, 
infection or diarrheal disease. It has an acute beginning, 
and the nadir is generally reached in less than four weeks. 
In contrast, the symptoms of CIDP typically have a longer 
progression of around eight weeks. Unlike GBS, patients 
with CIDP may experience a recurrent course of symptoms, 
and CIDP is rarely associated with a previous event, like a 
vaccination or illness. In addition, the involvement of the 
respiratory musculature, autonomic nervous system and 
peripheral nerves are rare, and they are associated with 
advanced disease states1,3,8.
Pathogenesis and Pathophysiology
CIDP is an autoimmune disease generated by 
cellular and humoral immune responses, which, acting 
synergistically, will act against peripheral nerve antigens, 
generating demyelination and often secondary, axonal 
degeneration2. There are reports of patients who report 
infections prior to the onset of neurological symptoms; 
however, there is still not enough evidence to relate 
infectious events to the onset of the disease6,9. In fact, the 
autoimmune etiology is well accepted for the efficacy of 
treatments to the immune system, such as IVIg, plasma 
exchange and use of corticosteroids, and through the 
evidence of the inflammatory response of blood and the 
peripheral nerves2,10.
The main inflammatory components found in the 
peripheral nerves after death are T cells and macrophages 
in the epineurium and endoneurium; macrophages are 
considered final effector cells after the demyelination 
process. Studies suggest that these T cells activate in the 
peripheral nervous system and generate the production 
of pro-inflammatory cytokines that produce a cytotoxic 
activity against myelin4,10. This process occurs through the 
alteration of the blood hematoneural barrier, which, under 
normal conditions, will maintain endoneurium homeostasis, 
preventing the free movement of soluble factors, such as 
serum blood proteins, to the nerve microenvironment1,2,11. 
When activated, T cells will adhere to endothelial cells, 
interacting with adhesion molecules and then migrating 
through the hematoneural barrier1. As they migrate through 
blood vessels, T cells continue to secrete inflammatory 
mediators, such as metalloproteinase and pro-inflammatory 
cytokines, contributing to increased permeability of the 
hematoneural barrier and generating a positive regulation 
of the immune response to the nerve2.
T cells do, in fact, appear to play a crucial role 
in the evolution of this disease. Studies show that the 
imbalance between Th1 and Th2 cells plays an important 
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role in the development of inflammatory and autoimmune 
diseases, including CIDP12. In addition, studies have shown 
that another subset of T cells, called Th17 cells, may be 
responsible for pathogenic effects previously attributed 
to Th1 cells13. Th17 cells were identified in animal and 
human models, which were associated with the orphan 
factor related to the retinoic acid receptor (ROR) and 
STAT3 (signal transducers and activators of transcription), 
in addition to an extensive network of pro-inflammatory 
cytokines, which include some interleukins11,12.
Additionally, evidence supports that the 
arachidonic acid pathway is highly activated in the 
nervous system of patients with multiple sclerosis, and 
this also seems to be true in patients with CIDP14. It has 
been demonstrated that COX-2 is expressed both in active 
demyelinating lesions and in oligodendrocytes, Schwann 
cells, macrographs and microglia in the process of cell 
death, which is a possible target for investigation in future 
research on the pathophysiology of this disease14,15.
Although CDIP is known to be caused by 
the loss of immune response regulation in response to 
unknown antigens, some myelin-related antibodies have 
been considered as potential autoantigens, including the 
myelin zero protein, myelin basic protein, connexin-32 and 
ganglioside. In general, the mechanisms for the generated 
immune responses and their repercussions in the peripheral 
nervous system have not yet been fully elucidated7,16,17.
Clinical features
In their classic form, the clinical manifestations 
of CIDP are monophasic, progressive or relapsing, 
symmetrical and evolve slowly over at least two months. 
Numbness, paresthesia, sensory changes, muscle weakness, 
hyporeflexia or areflexia, fatigue and imbalance are the 
main clinical findings that usually begin in the lower limbs. 
In rare cases, the cranial nerves can be affected, especially 
the seventh pair4,7.
The typical form of the disease corresponds to 
50% of the cases, with the remainder being variations of 
the classic form with motor or sensory predominance, 
presentation in the upper limbs or asymmetric presentation, 
such as Lewis-Sumner syndrome (Table 1)2,6.
CIDP can also affect children, usually between 5 and 
18 years old, and can cause serious disabilities if not treated 
properly. In general, children respond well to treatment and 
tend to have a better outcome compared to adults. Some 
children may show complete remission of CIDP or residual 
stability of the condition without the need for additional 
interventions1,17,18.
When the disease progresses, the patient may report 
difficulty in performing functional activities, such as going 
up and down stairs, difficulty in walking and getting up from 
a chair, falls and decreased manual dexterity in activities 
such as buttoning blouses and zipping. Approximately 50% 
of patients with CIDP will experience severe temporary 
disabilities, including not walking without a walking aid or 
wheelchair restriction, and 10% will have a persistent and 
progressive disability or will die from complications related 
to the disease. Some patients, however, may experience the 
disease with only subtle clinical manifestations, and some 
may even be asymptomatic1,6,19.
Table 1. Differences clinical presentation of CIDP
Clinical Presentation Onset Clinical Symptoms Distribution
Typical CIDP Chronic Sensory and motor Symmetrical, proximal, and distal
Sensory CIDP Chronic Sensory predominant; motor involvement may develop As per typical CIDP
Lewis-Sumner syndrome Chronic Sensory and motor Asymmetrical; often upper limb onset
Focal CIDP Chronic Sensory and motor Focal; may progress to diffuse CIDP over time
Motor CIDP Chronic Motor predominant As per typical CIDP
Acute onset CIDP Acute onset Sensory and motor As per typical CIDP
Legends: CIDP: Chronic inflammatory demyelinating polyradiculoneuropathy. Adapted table from Mathey et al.2
Pharmacological treatment
One of the primary goals of the treatment of 
CIDP is to reduce or attenuate the evolution of symptoms 
(muscle weakness, fatigue, sensory loss, alteration of 
balance control). The three main types of pharmacological 
treatments for CIDP are the intravenous administration of 
immunoglobulins, corticosteroids and plasma transfer. The 
response rate is 53%–80% for plasmapheresis, 40%–60% 
for corticosteroids and 54%–63% for the administration of 
immunoglobulins, according to prospective studies10,20-23.
In general, the use of prednisone or dexamethasone, 
immunoglobulins or plasma transfer have very similar 
effects in the short term, and in the long term, the choice 
should be made based on the individual characteristics 
and preference of the patient due to the adverse effects 
of the treatments. Treatment with prednisone is usually 
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started if the patient does not have contraindications, 
such as hypertension, osteoporosis, diabetes or obesity. 
If the administration of corticosteroids is not effective, 
immunoglobulins can be used, followed by plasma 
transfer1,6,24.
The treatment of patients with PDIC should be 
well thought out in relation to the cost-benefit of treatment 
options due to the adverse effects that may negatively 
impact the patients’ quality of life. The participation of a 
multidisciplinary team is also important in order to offer 
the patient a more targeted and integrated treatment.
Non-pharmacological treatment
Several studies highlight the importance of physical 
activity for CIDP patients’ quality of life. Indeed, the 
symptoms presented by these patients, including fatigue, 
could be attenuated with physical activities and physical 
exercise25.
Physical therapy can benefit patients with CIDP 
by employing activities that help to maintain range of 
motion, strengthen specific muscles, prevent shortening and 
contractures, sensorimotor stimulation, improve balance 
and gait training in order to avoid possible falls19. In turn, 
physical educators can play an important role in prescribing 
physical activities and exercises in order to reduce fatigue, 
which is often experienced by CIDP patients, and improve 
cardiorespiratory fitness. In addition, physical exercise can 
mitigate negative psychological aspects of the disease, such 
as anxiety, depression, anger and frustration26,27.
Physical education and physical therapy could use 
important therapeutic resources to prevent complications 
caused by the disease, as well as to improve physical well-
being and quality of life. A multidisciplinary and integrated 
approach can generate greater benefits for CIDP patients.
FINAL CONSIDERATIONS
Understanding CIDP is crucial for selecting the 
best pharmacological treatment options and consequently 
improving the patient’s physical well-being.
Future studies are necessary to understand the 
pathophysiology of this disease, as well as to improve 
the criteria for diagnosis. There is also a need for studies 
that observe the real benefits of non-pharmacological 
interventions to patient health.
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